China National Medicines (SHSE:600511) 5-Year EBITDA Growth Rate: 5.30% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:600511 China National Medicines Corp Ltd SHSE:600511
87 GF Score
Price ¥26.37
GF Value ¥32.17
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is China National Medicines 5-Year EBITDA Growth Rate?

China National Medicines SHSE:600511 -1.42% 87 5-Year EBITDA Growth Rate is 5.30% as of Jun. 2026. GuruFocus rates SHSE:600511 with a GF Score™ of 87/100 and a GF Value™ of ¥32.17 (Modestly Undervalued). The stock has 3 warning signs investors should review.

China National Medicines's EBITDA per Share for the three months ended in Jun. 2026 was ¥0.72.

During the past 12 months, China National Medicines's average EBITDA Per Share Growth Rate was -2.20% per year. During the past 3 years, the average EBITDA Per Share Growth Rate was -0.40% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 5.30% per year. During the past 10 years, the average EBITDA Per Share Growth Rate was 7.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of China National Medicines was 59.90% per year. The lowest was -0.40% per year. And the median was 17.80% per year.

China National Medicines  (SHSE:600511) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.

China National Medicines 5-Year EBITDA Growth Rate Related Terms

SHSE:600511 vs MCK, COR, CAH: 5-Year EBITDA Growth Rate Comparison

For the Medical Distribution subindustry, China National Medicines's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

China National Medicines 5-Year EBITDA Growth Rate vs Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, China National Medicines's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where China National Medicines's 5-Year EBITDA Growth Rate falls into.


SHSE:600511
87GF Score
China National Medicines Corp Ltd SHSE:600511
5-Year EBITDA Growth Rate is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

China National Medicines 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

What does a 5-Year EBITDA Growth Rate of 5.30% mean?
China National Medicines (SHSE:600511) has a 5-Year EBITDA Growth Rate of 5.30% as of Jun. 2026. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for China National Medicines and its competitors.
Is China National Medicines' 5-Year EBITDA Growth Rate too high?
China National Medicines' current 5-Year EBITDA Growth Rate is 5.30%. Overall, China National Medicines has a GF Score™ of 87/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does China National Medicines' 5-Year EBITDA Growth Rate compare to MCK and COR?
China National Medicines' 5-Year EBITDA Growth Rate of 5.30% can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year EBITDA Growth Rate for a Medical Distribution company?
A good 5-Year EBITDA Growth Rate depends on the Medical Distribution industry context. However, 5-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year EBITDA Growth Rate mean?
A high 5-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for China National Medicines and its competitors. China National Medicines's current 5-Year EBITDA Growth Rate is 5.30%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China National Medicines stock overvalued right now?
Based on GuruFocus' analysis, China National Medicines (SHSE:600511) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥32.17, compared to a current price of ¥26.37 — trading 18% below its estimated fair value. The current 5-Year EBITDA Growth Rate is 5.30%. China National Medicines' overall GF Score™ is 87/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year EBITDA Growth Rate calculated?
5-Year EBITDA Growth Rate is calculated from a company's financial statements. For China National Medicines (SHSE:600511), the current 5-Year EBITDA Growth Rate is 5.30% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is China National Medicines (SHSE:600511) Overvalued in 2026?

Based on GuruFocus' analysis, China National Medicines stock appears to be undervalued. The current stock price of ¥26.37 is trading 18% below its estimated GF Value™ of ¥32.17. GuruFocus considers China National Medicines to be Modestly Undervalued.

Key valuation signals for SHSE:600511:

  • 5-Year EBITDA Growth Rate: 5.30%
  • GF Value™: ¥32.17 vs. price of ¥26.37 (18% below fair value)
  • GF Score™: 87/100 with 3 warning signs

No single metric tells the full story. See the SHSE:600511 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

China National Medicines Business Description

Address No. 8, Xibinhe Road, Floor 6-9, West Tower, 7th Floor, Yongdingmen, Dongcheng District, Beijing, CHN, 100077
China National Medicines Corp Ltd focuses on producing special drugs and high-end prescription drugs. Its main goal is to provide customers with professional medical services. The company conducts its operations through two primary segments. The Commercial segment is mainly engaged in the sale of pharmaceuticals. The Others segment focuses on pharmaceutical manufacturing and logistics operations.
87GF Score

Get the complete analysis for SHSE:600511

5-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥26.37
Price
¥32.17
GF Value